Cannabis use is not associated with the development of psychosis in an 'ultra' high-risk group

Australian and New Zealand Journal of Psychiatry

Volumn 36, Issue 6, 2002, Pages 800-806

  Phillips, Lisa J ^a   Curry, Christina ^b   Yung, Alison R ^b   Yuen, Hok Pan ^b   Adlard, Steven ^a   McGorry, Patrick D ^b  

^a PACE Clinic   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Cannabis; High risk; Prodrome; Psychosis; Survival analysis

Indexed keywords

CANNABIS;

ADOLESCENT; ADULT; ARTICLE; CANNABIS ADDICTION; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FUNCTIONAL DISEASE; HIGH RISK POPULATION; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MEDICAL RESEARCH; PATIENT MONITORING; PSYCHOSIS; RELATIVE; RISK ASSESSMENT; RISK FACTOR; STATISTICAL ANALYSIS; SYMPTOM; PSYCHOLOGICAL ASPECT; SURVIVAL; TIME;

ADOLESCENT; ADULT; COHORT STUDIES; HUMANS; MARIJUANA ABUSE; PSYCHOTIC DISORDERS; RISK FACTORS; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 1842848543     PISSN: 00048674     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1614.2002.01089.x     Document Type: Article

References (48)

1. Miller F, Tanenbaum JH, Goodwin C, Igel J. Cocaine and polysubstance abuse by psychiatric inpatients. Hospital and Community Psychiatry 1990; 41:1251-1253.
2. Mueser KT, Yarnold PR, Levinson DF et al. Prevalence of substance abuse in schizophrenia: demographic and clinical correlates. Schizophrenia Bulletin 1990; 16:31-56.
3. Mueser KT, Yarnold PR, Rosenberg SD, Swett C Jr, Miles KM, Hill D. Substance use disorder in hospitalized severely mentally ill psychiatric patients: prevalence, correlates, and subgroups. Schizophrenia Bulletin 2000; 26:179-192.
4. Sembhi S, Lee JWY. Cannabis use in psychotic patients. Australian and New Zealand Journal of Psychiatry 1999; 33:529-532.
5. Tart C. Marijuana intoxication: common experiences. Nature 1970; 226:701-704.
6. Thomas H. Psychiatric symptoms in cannabis users. British Journal of Psychiatry 1993; 163:141-149.
7. Tien A, Anthony J. Epidemiological analysis of alcohol and drug use as risk factors for psychotic experiences. Journal of Nervous and Mental Disease 1990; 178:473-480.
8. Andreasson S, Allebeck P, Engstrom A, Rydberg U. Cannabis and schizophrenia: a longitudinal study of Swedish conscripts. Lancet 1987; 8574:1483-1485.
9. Ghodse A. Cannabis psychosis. British Journal of Addiction 1986; 81:473-478.
10. Brook JS, Brook DW, De La Rosa M et al. Pathways to marijuana use among adolescents: cultural/ecological, family, peer, and personality influences. Journal of the American Academy of Child and Adolescent Psychiatry 1998; 37:759-766.
11. Fergusson DM, Horwood LJ. Early onset cannabis use and psychosocial adjustment in young adults. Addiction 1997; 92:279-296.
12. Negrete JC. Cannabis and schizophrenia. British Journal of Addiction 1989; 84:349-351.
13. Thornicroft G. Cannabis and psychosis: is there epidemiological evidence for an association? British Journal of Psychiatry 1990; 157:25-33.
14. Cleghorn JM, Kaplan RD, Szechtman B, Szechtman H, Brown GM, Franco S. Substance use and schizophrenia: effect on symptoms but not on neuro-cognitive function. Journal of Clinical Psychiatry 1991; 52:26-30.
15. Cuffel BJ, Chase P. Remission and relapse of substance use disorders in schizophrenia: results from a one-year prospective study. Journal of Nervous and Mental Disease 1994; 182:342-348.
16. Linszen DH, Dingemans PM, Lenoir ME. Cannabis abuse and the course of recent-onset schizophrenic disorders. Archives of General Psychiatry 1994; 51:273-279.
17. Negrete JC, Knapp W, Douglas D, Smith WB. Cannabis affects the severity of schizophrenic symptoms: results of a clinical survey. Psychological Medicine 1986; 16:515-520.
18. Hall W. Cannabis use and psychosis. Drug and Alcohol Review 1998; 17:433-444.
19. Allebeck P, Adamsson C, Engstrom A. Cannabis and schizophrenia: a longitudinal study of cases treated in Stockholm County. Acta Psychiatrica Scandinavica 1993; 88:21-24.
20. Hambrecht M, Häfner H. Substance abuse and the onset of schizophrenia. Biological Psychiatry 1996; 40:1155-1163.
21. Hamera E, Schneider J, Stanley S. Alcohol, cannabis, nicotine, and cannabis use and symptom distress in schizophrenia. Journal of Nervous and Mental Disease 1995; 183:559-565.
22. McGorry PD, Yung AR, Phillips LJ et al. A randomized controlled trial of interventions designed to reduce the risk of progression to first episode psychosis in a clinical sample with subthreshold symptoms. Archives of General Psychiatry (in press).
23. McGorry PD, Yung AR, Phillips LJ. 'Closing in': what features predict the onset of first episode psychosis within a high risk group? In: Zipursky RB, Schulz SC, eds. The early stages of schizophrenia. Washington, DC: American Psychiatric Press, 2001; 3-32.
24. McGorry PD, Phillips LJ, Yung AR. Recognition and treatment of the pre-psychotic phase of psychotic disorders: frontier or fantasy? In: Miller T, Mednick SA, McGlashan TH, Libiger J, Johannssen JO, eds. Early intervention in psychiatric disorders. Netherlands: Kluwer, 2001; 101-122.
25. Yung AR, McGorry PD, McFarlane CA, Patton GC. The PACE Clinic: development of a clinical service for young people at high risk of psychosis. Australasian Psychiatry 1995; 3:345-349.
26. Yung AR, McGorry PD, McFarlane CA, Jackson HJ, Patton GC, Rakkar A. Monitoring and care of young people at incipient risk of psychosis. Schizophrenia Bulletin 1996; 22:283-303.
27. McGorry PD, Yung AR, Phillips LJ. Ethics and early intervention in psychosis: keeping up the pace and staying in step. Schizophrenia Research 2001; 51:17-29.
28. Phillips LJ, Yung AR, McGorry PD. Identification of young people at risk of psychosis: validation of the Personal Assessment and Crisis Evaluation Clinic intake criteria. Australian and New Zealand Journal of Psychiatry 2000; 34:S161-S163.
29. Yung AR, Phillips LJ, McGorry PD et al. Can we predict onset of first episode psychosis in a high risk group? International Clinical Psychopharmacology 1998; 13:S23-S30.
30. Yung AR, Phillips LJ, McGorry PD et al. The prediction of psychosis: a step towards indicated prevention. British Journal of Psychiatry 1998; 172 (Suppl. 33):14-20.
31. Yung AR, Phillips LJ, Yuen HP, McGorry PD, Francey SF, McFarlane CA. Psychosis prediction: 12 month follow-up of a high risk ('prodromal') group. Schizophrenia Research (in press).
32. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th edn. Washington, DC: American Psychiatric Association, 1994.
33. Wing JK, Babor T, Brugha T, Burke J. SCAN Schedules for clinical assessment in neuropsychiatry. Archives of General Psychiatry 1990; 47:589-593.
34. Heinrichs D, Hanlon T, Carpenter W. The Quality of Life Scale: an instrument for rating the schizophrenia deficit syndrome. Schizophrenia Bulletin 1984; 10:388-398.
35. McGorry PD, Goodwin RJ, Stuart GW. The development, use and reliability of the Brief Psychiatric Rating Scale (Nursing Modification): an assessment procedure for the nursing team in clinical and research settings. Comprehensive Psychiatry 1988; 29:575-587.
36. Hamilton M. The assessment of anxiety states by rating. British Journal of Psychiatry 1959; 32:50-55.
37. Hamilton M. A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry 1960; 23:56-61.
38. Andreasen N. Negative symptoms in schizophrenia. Definition and Reality Archives of General Psychiatry 1982; 39:784-788.
39. King M, Coker E, Leavey G, Hoare A, Johnson-Sabine E. Incidence of psychotic illness in London: comparison of ethnic groups. British Medical Journal 1994; 309:1115-1119.
40. Kovasznay B, Fleischer J, Tanenberg-Karant M, Jandorf L, Miller AD, Bromet E. Substance use disorder and the early course of illness in schizophrenia and affective psychosis. Schizophrenia Bulletin 1997; 23:195-201.
41. Rabinowitz J, Bromet EJ, Lavelle J, Carlson G, Kovasznay B, Schwartz JE. Prevalence and severity of substance use disorders and onset of psychosis in first-admission psychotic patients. Psychological Medicine 1998; 28:1411-1419.
42. Edwards J, Hinton M, Elkins K, Athansopolous O. Cannabis and early psychosis. In: Graham H, Mueser K, Birchwood M, Copello A, eds. Substance misuse in psychosis: approaches to treatment and service delivery. Chichester: Wiley (in press).
43. Swift W, Hall W, Teesson M. Characteristics of DSM-IV and ICD-10 cannabis dependence among Australian adults: results from the National Survey of Mental Health and Wellbeing. Drug and Alcohol Dependence 2001; 63:147-153.
44. Rey JM, Sawyer MG, Raphael B, Patton GC, Lynskey M. Mental health of teenagers who use cannabis: Results of an Australian survey. British Journal of Psychiatry 2002; 180:216-221.
45. Jones R. Drug of abuse profile. Cannabis Clinical Chemistry 1987; 33:72B-81B.
46. Solowij N. Differential impairments of selective attention due to frequency and duration of cannabis use. Biological Psychiatry 1995; 37:731-739.
47. Brewer WJ, Pantelis C, Anderson V et al. Stability of olfactory identification deficits in neuroleptic-naive patients with first episode psychosis. American Journal of Psychiatry 2001; 158:107-115.
48. Andreasen NC, Flaum M, Arndt S. The Comprehensive Assessment of Symptoms and History (CASH): an instrument for assessing diagnosis and psychopathology. Archives of General Psychiatry 1992; 49:615-623.